Reference
Caprelsa (vandetanib) - Important Safety Information from Sanofi-Aventis Ireland Limited as approved by the HPRA (10.01.23) Internet Document : 27 Jan 2023. Available from: URL: https://www.hpra.ie/homepage/medicines/safety-notices/item?t=/caprelsa-(vandetanib)---important-safety-information-from-sanofi-aventis-ireland-limited-as-approved-by-the-hpra-(10.01.2023)&id=40b01326-9782-6eee-9b55-ff00008c97d0
Rights and permissions
About this article
Cite this article
Restriction of indication for vandetanib. Reactions Weekly 1943, 6 (2023). https://doi.org/10.1007/s40278-023-32891-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-32891-8